Navigation Links
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Date:2/7/2008

BRIDGEWATER, N.J., Feb. 7 /PRNewswire/ -- New data showed that at 48 weeks, significantly more treatment-experienced adults with HIV-1 with documented resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) had an undetectable viral load (defined as less than 50 HIV-1 RNA copies/mL) with INTELENCE (etravirine) tablets plus a background regimen (BR) compared with placebo plus a BR. These findings from two ongoing double-blind, placebo-controlled, randomized Phase 3 studies (DUET-1 and DUET-2) were presented at the 15th Conference on Retroviruses and Opportunistic Infections in Boston.

In the DUET-1 and -2 studies, 60 percent and 61 percent of patients in the INTELENCE arms had a confirmed undetectable viral load at 48 weeks compared with 39 percent and 41 percent of those in the placebo arms, respectively. In each study, this difference was significant [p<0.0001].

INTELENCE, a new NNRTI from Tibotec, received accelerated approval from the U.S. Food and Drug Administration (FDA) on January 18, 2008. It is the first NNRTI to receive approval in almost ten years. INTELENCE received approval based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled DUET-1 and -2 studies. The 48-week results will be filed with the FDA for consideration of traditional approval of INTELENCE.

"Etravirine is an important new option for treatment-experienced patients with NNRTI resistance and these data build upon the 24-week data that had previously been available," said Richard Haubrich, M.D., Professor of Medicine, Division of Infectious Diseases, University of California, San Diego, and investigator in the INTELENCE Phase 3 DUET studies.

INTELENCE, in combination with other antiretroviral (ARV) agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication an
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
3. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
4. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
5. Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
6. Vanda Presents Phase III Iloperidone Efficacy Data
7. Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
8. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
11. Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... BioMarin, will present a company update at the Citi Global ... 2011 at 8:00 a.m. ET.   Interested parties ... via the investor section of the BioMarin website, www.BMRN.com ...
... Mich., Feb. 22, 2011 Perrigo Company (Nasdaq: ... filed an Abbreviated New Drug Application for calcipotriene 0.005% ... Taclonex® Ointment. Another generic company is the first to ... Betamethasone) ointment is indicated for the topical treatment of ...
Cached Medicine Technology:BioMarin to Present at the Citi Global Healthcare Conference 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 3
(Date:7/11/2014)... Cancer researchers in Slovenia say genetic variations ... how patients respond to treatment with pemetrexed (Alimta), the ... the full story. Click here to read the ... of Ljubljana and the Ljubljana Institute of Oncology tested ... of polymorphisms. They found that patients with genetic variations ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
(Date:7/11/2014)... Woodland Hills permanent teeth in one day ... Institute in Woodland Hills and Oxnard, Calif., will speak next ... Rey, Calif. , The award-winning prosthodontist, international speaker and ... in one day dental procedure at 1:30 p.m. Friday, July ... 15 years ago, Dr. Jivraj said. Getting new teeth in ...
(Date:7/11/2014)... 11, 2014 BellasDress, the experienced dressmaker ... popular online suppliers when it comes to beach ... new collection of beach wedding outfits in its online ... of elegant outfits. , BellasDress has been considered ... world. According to the company’s senior spokesman, BellasDress provides ...
(Date:7/11/2014)... The International Concussion Organization is ... Best Buy Theater in Times Square, New York ... growing concussion epidemic that is plaguing athletes in ... competition. , The Symposium gathers more than a ... professional athletes and legal scholars for engaging and ...
Breaking Medicine News(10 mins):Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2
... statistically significant decline in prostate specific antigen (PSA) levels, ... issue of the Journal of the National Cancer ... was associated with a reduction in prostate cancer risk. ... examined the association between statins and PSA level. ...
... PAUL, Minn., Oct. 28 Dean Barkley,candidate for US Senate ... to fight HIV/AIDS in the US and around the world., ... candidates from,Minnesota will also agree to sign the pledge," said ... "The pledge helps,voters see who is prepared to take a ...
... (Nasdaq: AHII ) announced today that the Company ... quarter ended,September 30, 2008 on Tuesday, November 4, 2008. ... same day at 10:00 a.m.,Eastern Standard Time to discuss ... access the conference call by dialing (719) 785-1758.,Participants will ...
... drug delayed disease progression, researchers found , , WEDNESDAY, Oct. ... to treat erectile dysfunction, appears effective in treating pulmonary ... high blood pressure in the arteries that supply the ... can become tired, dizzy and short of breath, because ...
... INDIANAPOLIS, Oct. 28 WellPoint, Inc. (NYSE:,WLP) announced ... at the,following conferences:, -- Oppenheimer 19th Annual ... Eastern Standard Time ("EST"); and, -- 2008 ... at,9:30 a.m. Mountain Standard Time (11:30 a.m. EST)., ...
... Corporation,(NYSE: DHR ) announced that Executive Vice ... be presenting at the Goldman Sachs Global,Industrials Conference ... 2008 at,8:00 a.m. EST. The audio will be ... Corporation is a leading manufacturer of Professional,Instrumentation, Medical ...
Cached Medicine News:Health News:Statin use associated with reduction in prostate specific antigen levels 2Health News:Senator Dean Barkley Pledges Action on HIV/AIDS Epidemic 2Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2
Supplied sterile in peel-open packages. Intended for one-time use....
... Used for catheter ... endourology procedures. Increased inner ... coils allows utilization of ... mandril while maintaining tip ...
Supplied sterile in peel-open packages. Intended for one-time use....
... access wire into the renal pelvis through a ... The mandril type shaft construction provides rigidity which ... (0.89 mm) diameter wire guide. The distal portion ... construction over the tapered mandril which provides tip ...
Medicine Products: